Media headlines about Celgene (NASDAQ:CELG) have trended somewhat positive on Tuesday, according to Accern. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Celgene earned a news impact score of 0.20 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.8119886025976 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:
- Celgene Co. (CELG) Director Sells $851,092.50 in Stock (americanbankingnews.com)
- Near a 3-Year Low, Is Celgene Stock a Buy? (finance.yahoo.com)
- Southwest Airlines Co., (NYSE: LUV), Celgene Corporation, (NASDAQ: CELG) – Notable Stock’s Stunning Activities: – Global Export Lines (press release) (globalexportlines.com)
- Strategic Advisors LLC Trims Stake in Celgene Co. (CELG) – ExpressNewsline (expressnewsline.com)
- Jounce Therapeutics Is on Track to Report Key Data Soon – Madison.com (host.madison.com)
Several equities research analysts have recently weighed in on CELG shares. Mizuho reissued a “buy” rating and issued a $128.00 price objective on shares of Celgene in a research report on Sunday, February 4th. Credit Suisse Group set a $125.00 price objective on Celgene and gave the company a “buy” rating in a research report on Monday, January 8th. Vetr cut Celgene from a “strong-buy” rating to a “buy” rating and set a $121.72 price objective for the company. in a research report on Monday, December 18th. Cann reissued a “buy” rating and issued a $163.00 price objective on shares of Celgene in a research report on Thursday, February 15th. Finally, Leerink Swann reissued a “buy” rating and issued a $120.00 price objective on shares of Celgene in a research report on Wednesday, December 13th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $128.22.
Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.78 by $0.09. The company had revenue of $3.48 billion during the quarter, compared to analysts’ expectations of $3.46 billion. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The business’s revenue was up 16.9% on a year-over-year basis. During the same period last year, the business earned $1.61 earnings per share. equities analysts forecast that Celgene will post 7.66 EPS for the current year.
Celgene declared that its Board of Directors has initiated a share buyback plan on Wednesday, February 14th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares buyback plans are typically an indication that the company’s board believes its shares are undervalued.
In other Celgene news, insider Mark J. Alles bought 3,260 shares of the stock in a transaction dated Thursday, February 8th. The stock was bought at an average cost of $91.90 per share, for a total transaction of $299,594.00. Following the completion of the purchase, the insider now owns 178,904 shares in the company, valued at approximately $16,441,277.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $95.99, for a total value of $887,907.50. Following the completion of the sale, the director now owns 94,801 shares of the company’s stock, valued at $9,099,947.99. The disclosure for this sale can be found here. Over the last three months, insiders have sold 41,120 shares of company stock valued at $3,879,509. Company insiders own 0.95% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Celgene (CELG) Stock Price” was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://baseballnewssource.com/2018/03/13/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-celgene-celg-stock-price/2025532.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.